BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1026 related articles for article (PubMed ID: 22615102)

  • 1. Mantle cell lymphoma: 2012 update on diagnosis, risk-stratification, and clinical management.
    Vose JM
    Am J Hematol; 2012 Jun; 87(6):604-9. PubMed ID: 22615102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mantle cell lymphoma: 2013 Update on diagnosis, risk-stratification, and clinical management.
    Vose JM
    Am J Hematol; 2013 Dec; 88(12):1082-8. PubMed ID: 24273091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mantle cell lymphoma: 2015 update on diagnosis, risk-stratification, and clinical management.
    Vose JM
    Am J Hematol; 2015 Aug; 90(8):739-45. PubMed ID: 26103436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management.
    Vose JM
    Am J Hematol; 2017 Aug; 92(8):806-813. PubMed ID: 28699667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network.
    Hoster E; Klapper W; Hermine O; Kluin-Nelemans HC; Walewski J; van Hoof A; Trneny M; Geisler CH; Di Raimondo F; Szymczyk M; Stilgenbauer S; Thieblemont C; Hallek M; Forstpointner R; Pott C; Ribrag V; Doorduijn J; Hiddemann W; Dreyling MH; Unterhalt M
    J Clin Oncol; 2014 May; 32(13):1338-46. PubMed ID: 24687837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Follicular lymphoma: 2012 update on diagnosis and management.
    Freedman A
    Am J Hematol; 2012 Oct; 87(10):988-95. PubMed ID: 23001911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma.
    Mangel J; Buckstein R; Imrie K; Spaner D; Crump M; Tompkins K; Reis M; Perez-Ordonez B; Deodhare S; Romans R; Pennell N; Robinson JB; Hewitt K; Richardson P; Lima A; Pavlin P; Berinstein NL
    Semin Oncol; 2002 Feb; 29(1 Suppl 2):56-69. PubMed ID: 11842390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi.
    Merli F; Luminari S; Ilariucci F; Petrini M; Visco C; Ambrosetti A; Stelitano C; Caracciolo F; Di Renzo N; Angrilli F; Carella AM; Capodanno I; Barbolini E; Galimberti S; Federico M
    Br J Haematol; 2012 Feb; 156(3):346-53. PubMed ID: 22145911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur.
    Geisler CH; Kolstad A; Laurell A; Jerkeman M; Räty R; Andersen NS; Pedersen LB; Eriksson M; Nordström M; Kimby E; Bentzen H; Kuittinen O; Lauritzsen GF; Nilsson-Ehle H; Ralfkiaer E; Ehinger M; Sundström C; Delabie J; Karjalainen-Lindsberg ML; Brown P; Elonen E;
    Br J Haematol; 2012 Aug; 158(3):355-62. PubMed ID: 22640180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic impact of monocyte count at presentation in mantle cell lymphoma.
    von Hohenstaufen KA; Conconi A; de Campos CP; Franceschetti S; Bertoni F; Margiotta Casaluci G; Stathis A; Ghielmini M; Stussi G; Cavalli F; Gaidano G; Zucca E
    Br J Haematol; 2013 Aug; 162(4):465-73. PubMed ID: 23808798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma.
    Romaguera JE; Fayad LE; Feng L; Hartig K; Weaver P; Rodriguez MA; Hagemeister FB; Pro B; McLaughlin P; Younes A; Samaniego F; Goy A; Cabanillas F; Kantarjian H; Kwak L; Wang M
    Br J Haematol; 2010 Jul; 150(2):200-8. PubMed ID: 20528872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proliferation predicts failure-free survival in mantle cell lymphoma patients treated with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with rituximab plus high-dose methotrexate and cytarabine.
    Garcia M; Romaguera JE; Inamdar KV; Rassidakis GZ; Medeiros LJ
    Cancer; 2009 Mar; 115(5):1041-8. PubMed ID: 19170236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. R-CHOP or R-HyperCVAD with or without autologous stem cell transplantation for older patients with mantle cell lymphoma.
    Frosch Z; Luskin MR; Landsburg DJ; Schuster SJ; Svoboda J; Loren AW; Porter DL; Stadtmauer EA; Nasta SD
    Clin Lymphoma Myeloma Leuk; 2015 Feb; 15(2):92-7. PubMed ID: 25174772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. R-hyper-CVAD versus R-CHOP/cytarabine with high-dose therapy and autologous haematopoietic stem cell support in fit patients with mantle cell lymphoma: 20 years of single-center experience.
    Widmer F; Balabanov S; Soldini D; Samaras P; Gerber B; Manz MG; Goede JS
    Ann Hematol; 2018 Feb; 97(2):277-287. PubMed ID: 29147847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Follicular lymphoma: 2014 update on diagnosis and management.
    Freedman A
    Am J Hematol; 2014 Apr; 89(4):429-36. PubMed ID: 24687887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A patient with mantle cell lymphoma who successfully underwent auto-PBSCT in combination with in vivo purging of tumor cells using rituximab].
    Kanaji N; Ishibashi K; Uno H; Hino N
    Gan To Kagaku Ryoho; 2002 Dec; 29(13):2569-72. PubMed ID: 12506485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma.
    Ladetto M; Magni M; Pagliano G; De Marco F; Drandi D; Ricca I; Astolfi M; Matteucci P; Guidetti A; Mantoan B; Bodoni CL; Zanni M; Boccadoro M; Gianni AM; Tarella C
    Biol Blood Marrow Transplant; 2006 Dec; 12(12):1270-6. PubMed ID: 17162208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of eukaryotic initiation factor 4E predicts clinical outcome in patients with mantle cell lymphoma treated with hyper-CVAD and rituximab, alternating with rituximab, high-dose methotrexate, and cytarabine.
    Inamdar KV; Romaguera JE; Drakos E; Knoblock RJ; Garcia M; Leventaki V; Medeiros LJ; Rassidakis GZ
    Cancer; 2009 Oct; 115(20):4727-36. PubMed ID: 19708031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network.
    Hoster E; Rosenwald A; Berger F; Bernd HW; Hartmann S; Loddenkemper C; Barth TF; Brousse N; Pileri S; Rymkiewicz G; Kodet R; Stilgenbauer S; Forstpointner R; Thieblemont C; Hallek M; Coiffier B; Vehling-Kaiser U; Bouabdallah R; Kanz L; Pfreundschuh M; Schmidt C; Ribrag V; Hiddemann W; Unterhalt M; Kluin-Nelemans JC; Hermine O; Dreyling MH; Klapper W
    J Clin Oncol; 2016 Apr; 34(12):1386-94. PubMed ID: 26926679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 52.